EN DE
STOCK COMPARISON

Abbott Laboratories vs Gilead: Fair Value & Quality

Both stocks run through our valuation models. Here is how Abbott Laboratories (ABT) and Gilead (GILD) compare, as of Nov 13, 2026.

As of Nov 13, 2026, Fair Value Calculator sees Gilead as the more attractively valued of the two: Abbott Laboratories trades at $109 versus a fair value of $75.28 (−30.6%), while Gilead trades at $168 versus $185 (+9.9%).
Abbott Laboratories
ABT · USD · Health Care
−30.6%
upside to fair value
overvalued
Price$109
Fair Value$75.28
Quality68/100
Fair ValueQualityUptrend
Gilead
GILD · USD · Health Care
+9.9%
upside to fair value
fairly valued
Price$168
Fair Value$185
Quality81/100
Fair ValueQualityUptrend
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.

betterweakerfor reference, not scored

Abbott LaboratoriesGilead
Valuation
41.1×P/E (TTM)n/a
29.1×P/E ex one-offs (FY2025)23.2×
18.3×Forward P/E (FY2027)16.7×
35.6×Median P/E at FY-end (ex one-offs where documented)15.8×
3.92×P/S (TTM)6.74×
3.63×P/B9.24× · book value is mostly intangible assets
15.9×EV/EBITDA14.6×
1.50×PEG2.52×
−30.6%Fair value upside+9.9%
2.3%Dividend yield1.9%
$2.52Dividend per share$3.25
Profitability
11.3%Operating margin43.4%
1.19×EBIT margin trend (5Y)2.41×
10.6%Return on equity-22.5%
7.5%Return on assets14.4%
Growth
14.5%Revenue growth (YoY)6.8%
0.5%Avg. growth/yr (3Y)2.6%
5.1%Avg. growth/yr (5Y)3.6%
+10.5%Value creation/yr+10.3%
Balance & size
23.6×Interest coverage (EBIT/interest)11.4×
0.19×Debt / equity0.98×
$189BMarket cap$209B
healthyGrowth qualityhealthy
The P/E excluding one-off items is only shown where the special items are documented in the accounts (our own raw data or SEC filings). If one side lacks it, the reported P/E stays scored.
Abbott Laboratories, median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings, FY2016, FY2020, FY2023 ex one-offs: 35.6. Gilead, median P/E at fiscal year-end, 10 fiscal years (2016 to 2025), reported earnings, 8 of the years ex one-offs: 15.8.
Forward P/E: price divided by the analyst consensus for the first fiscal year that has not started yet. The current year carries special items from quarters already reported.

Abbott Laboratories leads: 7 to 6 metric wins.

n/a = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Abbott Laboratories Gilead
ProfitabilityHow much profit the company makes from its sales and capital
50
77
Quality GrowthAre margins and returns getting better?
47
67
CashflowDo the profits arrive as real cash?
71
86
Financial strengthDebt, balance sheet and risk of trouble
80
64
InvestmentDoes it invest with discipline instead of growing at any price?
65
97
Low VolatilityHow calm the share price moves, does not count
82
87
Price momentumPrice momentum of the last 3 to 12 months, does not count
46
75
Near the 52-week highDistance to the 52-week high, does not count
39
83
New sharesBuys back shares or issues new ones?
83
89

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyAbbott LaboratoriesPrice $109GileadPrice $168
DCF Models−24.9%below the price$81.54+31.9%above the price$222
Earnings-Based−61.2%below the price$42.11−23.2%below the price$129
Dividend Discount−45.9%below the price$58.68−46.4%below the price$90.05
Multiples−35.8%below the price$69.69−12.8%close to the price$147
Asset-Based−91.9%below the price$8.74n/a
Growth DCF−31.2%below the price$74.64+26.9%above the price$213
Economic Profit−62.2%below the price$41.05−32.6%below the price$113
Growth Earnings−34.8%below the price$70.720%close to the price$167
Matching families7 of 8
Minimum−62.2%below the price$41.05−46.4%below the price$90.05
Maximum−24.9%below the price$81.54+31.9%above the price$222
Median−35.8%below the price$69.69−12.8%close to the price$147
Geometric mean−44.0%below the price$60.72−12.2%close to the price$148
Ahead family by family1 of 76 of 7

Minimum, maximum, median and geometric mean only use the families both stocks have (matching families: 7 of 8), so a family without a value on one side does not distort the comparison. Ahead in a family is the stock whose fair value there sits higher relative to its price. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Family by family: Gilead is ahead in 6 of 7 shared families, Abbott Laboratories in 1.

Abbott Laboratories: 26 of 26 models see the stock below the current price.

Gilead: 16 of 24 models see the stock below the current price.

Gilead: The fair value at the top is not the result of a single model. It starts from the evidence-weighted blend of the models and is adjusted afterwards, so it can sit above or below the models.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Abbott Laboratories
Price $109
Fair Value $75.28
Bear $52.65Bull $95.05
Gilead
Price $168
Fair Value $185
Bear $124Bull $240

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Abbott Laboratories · Health Care

Quality score68 · Top 25%
Fair value upside−30.6% · below median

Gilead · Health Care

Quality score81 · Top 25%
Fair value upside+9.9% · above median

Bottom line

As of Nov 13, 2026, Fair Value Calculator sees Gilead as the more attractively valued of the two: Abbott Laboratories trades at $109 versus a fair value of $75.28 (−30.6%), while Gilead trades at $168 versus $185 (+9.9%).

Gilead has the higher quality score (81/100).

Open Gilead live analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.